Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN

Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 108,044 shares of the biopharmaceutical company’s stock after purchasing an additional 1,486 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.10% of Regeneron Pharmaceuticals worth $60,750,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 0.9% during the 2nd quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after buying an additional 42,343 shares in the last quarter. Dodge & Cox raised its position in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after acquiring an additional 1,502,198 shares during the period. Franklin Resources Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.6% during the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after purchasing an additional 36,821 shares in the last quarter. Loomis Sayles & Co. L P grew its position in shares of Regeneron Pharmaceuticals by 18.6% in the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares during the period. Finally, Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $628,151,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ:REGN opened at $749.33 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock has a market cap of $78.75 billion, a P/E ratio of 17.94, a PEG ratio of 1.92 and a beta of 0.39. The business has a fifty day moving average of $752.97 and a two-hundred day moving average of $640.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the company posted $12.46 EPS. The company’s revenue was up .9% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Analyst Ratings Changes

A number of research analysts recently weighed in on REGN shares. Bank of America raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Insider Activity

In other news, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 8,431 shares of company stock valued at $5,733,521 in the last 90 days. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.